Covestor Ltd Has $65,000 Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Covestor Ltd raised its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 40.9% in the 3rd quarter, Holdings Channel reports. The firm owned 327 shares of the medical research company’s stock after purchasing an additional 95 shares during the quarter. Covestor Ltd’s holdings in Charles River Laboratories International were worth $65,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in CRL. Allspring Global Investments Holdings LLC lifted its position in shares of Charles River Laboratories International by 40.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock worth $346,821,000 after purchasing an additional 509,163 shares during the period. Epoch Investment Partners Inc. lifted its holdings in Charles River Laboratories International by 2,733.4% in the first quarter. Epoch Investment Partners Inc. now owns 247,501 shares of the medical research company’s stock valued at $67,060,000 after buying an additional 238,766 shares during the period. Marshall Wace LLP lifted its holdings in Charles River Laboratories International by 24.6% in the second quarter. Marshall Wace LLP now owns 825,905 shares of the medical research company’s stock valued at $170,615,000 after buying an additional 163,056 shares during the period. 1832 Asset Management L.P. acquired a new position in Charles River Laboratories International in the second quarter valued at $33,053,000. Finally, Earnest Partners LLC lifted its holdings in Charles River Laboratories International by 12.4% in the second quarter. Earnest Partners LLC now owns 1,004,486 shares of the medical research company’s stock valued at $207,507,000 after buying an additional 110,725 shares during the period. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Stock Down 4.6 %

CRL opened at $196.97 on Friday. The company has a 50 day moving average of $195.26 and a 200 day moving average of $207.82. The company has a market cap of $10.07 billion, a PE ratio of 24.65, a price-to-earnings-growth ratio of 5.57 and a beta of 1.38. Charles River Laboratories International, Inc. has a 12 month low of $176.48 and a 12 month high of $275.00. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $975.99 million. During the same period last year, the firm earned $2.72 EPS. The business’s quarterly revenue was down 1.6% compared to the same quarter last year. On average, sell-side analysts expect that Charles River Laboratories International, Inc. will post 10.18 EPS for the current year.

Charles River Laboratories International announced that its board has authorized a stock repurchase program on Wednesday, August 7th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the medical research company to repurchase up to 9.6% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s leadership believes its stock is undervalued.

Analyst Ratings Changes

CRL has been the topic of several research reports. Baird R W lowered shares of Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 8th. TD Cowen upped their price objective on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a report on Monday. Barclays lowered their target price on shares of Charles River Laboratories International from $230.00 to $210.00 and set an “equal weight” rating on the stock in a report on Thursday, August 8th. CLSA upgraded shares of Charles River Laboratories International from an “underperform” rating to a “hold” rating and set a $205.00 target price on the stock in a report on Thursday, November 7th. Finally, The Goldman Sachs Group lowered their target price on shares of Charles River Laboratories International from $290.00 to $250.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $217.54.

Insider Transactions at Charles River Laboratories International

In other news, Director Richard F. Wallman sold 6,621 shares of Charles River Laboratories International stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the sale, the director now directly owns 12,386 shares of the company’s stock, valued at approximately $2,676,862.32. The trade was a 34.83 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 1.30% of the stock is currently owned by insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).